Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting (TransFLUas)

October 30, 2017 updated by: University of Zurich

TransFLUas: Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting: A Prospective Study Over Two Consecutive Influenza Seasons

The epidemiology and transmission dynamics of influenza in hospitals are only poorly understood, particularly with respect to subjects without symptoms of influenza infection (e.g. without fever, cough, sore throat, nasal congestion, weakness, headache, loss of appetite, or myalgia). Knowledge about whether asymptomatic subjects are able to transmit influenza is of major importance. If they do transmit influenza, vaccination of patients and healthcare workers (HCW) before start of the influenza season, the permanent use of masks by HCW during influenza season, and quarantine for previously exposed inpatients may be the only available measures to reduce the number of influenza transmission events from asymptomatic subjects in acute care hospitals. Closure of this knowledge gap would be of major benefit to infection prevention and control recommendations, and may in turn reduce morbidity and mortality associated with influenza in hospitals through improved patient management.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The epidemiology and transmission dynamics of influenza in hospitals are only poorly understood, particularly with respect to subjects without symptoms of influenza infection (e.g. without fever, cough, sore throat, nasal congestion, weakness, headache, loss of appetite, or myalgia). Knowledge about whether asymptomatic subjects are able to transmit influenza is of major importance. If they do transmit influenza, vaccination of patients and healthcare workers (HCW) before start of the influenza season, the permanent use of masks by HCW during influenza season, and quarantine for previously exposed inpatients may be the only available measures to reduce the number of influenza transmission events from asymptomatic subjects in acute care hospitals.

The investigators' key aim is therefore to define whether exposure to asymptomatic subjects with influenza infection constitutes a risk for influenza transmission in an acute care hospital setting through active, prospective surveillance.

The investigators' secondary aims are to describe the prevalence of community-acquired symptomatic and asymptomatic influenza upon hospital admission and the incidence of asymptomatic and symptomatic nosocomial influenza among inpatients; to assess transmission dynamics of symptomatic influenza infection in acute care; and to study the incidence of asymptomatic and symptomatic influenza, absenteeism (i.e. being absent from work due to influenza), presenteeism (i.e. being present at work despite influenza infection) associated with influenza, and compliance with infection control recommendations to prevent spread of influenza in acute care HCW.

The investigators plan to enroll 1,260 inpatients and 180 HCW from medical wards at the University Hospital Zurich in a prospective study over two consecutive influenza seasons in order to detect at least one transmission event from an asymptomatic individual shedding influenza virus. Flocked mid-turbinate nasal swabs will be collected daily from consenting inpatients starting from day of admission until two days after discharge and from HCW over the influenza (winter) season and analyzed for influenza A and B using polymerase chain reaction. Simultaneously, signs and symptoms of influenza infection (including cough, sore throat, fever >37.8°C, nasal congestion, weakness, headache, loss of appetite or myalgia) as well as contact patterns between inpatients and HCW will be recorded. Reconstruction of influenza transmission chains will be based on phylogenetic analyses derived from next-generation sequence data and epidemiological contact tracing.

Study Type

Observational

Enrollment (Actual)

700

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Zurich, Switzerland
        • University Hospital Zurich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This project is a prospective study following patients in medical wards and acute care HCW (including nursing staff (nurses and assistant nurses), physiotherapists, house staff with direct patient contact and medical doctors (clinical fellows) working on the same wards at the University Hospital Zurich. Inpatients and HCW will be recruited from general medical and infectious diseases wards, pulmonology wards, hematology wards and from the stem cell transplant unit. All HCW and inpatients on the ward under surveillance are eligible for the study

Description

Inclusion Criteria:

  • 18 or more years of age;
  • Available for follow-up during the study period;
  • If a HCW: employed full- or part-time (≥50% full-time equivalent);
  • Understand the study, agree to its provisions, and give written informed consent (as documented by signature).

Exclusion Criteria:

  • If a HCW: planning to spend more than two consecutive weeks outside of Switzerland during the winter study period (November 1st to April 31st);
  • If a HCW: planning to take leave from work for more than two consecutive weeks during the winter study period (e.g. maternity or medical leave);
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the subject;
  • Known or suspected non-compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
surveillance cohort
Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary attack rate of asymptomatic or presymptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting
Time Frame: up to 6 months
diagnosed by positive influenza PCR from flocked mid-turbinate nasal swab collected in symptomatic or asymptomatic individuals following face-to-face contact with an individual with symptomatic influenza infection on the day of contact.
up to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary attack rate of symptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting
Time Frame: up to 6 months

Secondary attack rate of symptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting: as diagnosed by positive influenza PCR from flocked mid-turbinate nasal swab collected in symptomatic or asymptomatic individuals following face-to-face contact with an individual with symptomatic influenza infection on the day of contact. Transmissions will be considered 'proven' if confirmed by phylogenetic analyses. Specifically, we expect that whole-genome sequence analysis will demonstrate identical or almost identical influenza strains within transmission chains.

Transmissions will be considered 'probable' if there is epidemiological evidence of face-to-face contact and identical strains have been identified in PCR but whole-genome sequencing was technically unsuccessful;

up to 6 months
Proportion of asymptomatic and symptomatic inpatients with influenza infection upon hospital admission: as diagnosed by influenza polymerase chain reaction (PCR) from flocked mid-turbinate nasal swabs collected upon hospital admission
Time Frame: up to 6 months
diagnosed by influenza PCR from flocked mid-turbinate nasal swabs collected upon hospital admission
up to 6 months
Incidence of asymptomatic (A5) and symptomatic (A6) nosocomial influenza in hospital inpatients, defined as the number of emerging influenza infections >72 hours after hospital admissions per 100 patient-days
Time Frame: up to 6 months
diagnosed by PCR from flocked mid-turbinate nasal swabs collected three times per week over the influenza season
up to 6 months
Incidence of asymptomatic (A7) and symptomatic (A8) influenza in acute care hospital workers defined as the number of influenza infections per 100 HCW per influenza season
Time Frame: up to 6 months
diagnosed by influenza PCR from flocked mid-turbinate nasal swabs collected three times per week over the influenza season collected three times per week over the influenza season
up to 6 months
Association of individual influenza symptoms with influenza transmission from subjects with symptomatic influenza infection
Time Frame: up to 6 months
Association of individual influenza symptoms with influenza transmission from subjects with symptomatic influenza infection
up to 6 months
Influenza-attributable mortality in inpatients, expressed as infection-fatality rate, i.e. number of deaths among those infected
Time Frame: up to 6 months
number of deaths among those infected
up to 6 months
Absenteeism: as defined by total number of days absent from work due to PCR-proven influenza divided by total number of days due to work in HCW
Time Frame: up to 6 months
Absenteeism: as defined by total number of days absent from work due to PCR-proven influenza divided by total number of days due to work in HCW;
up to 6 months
Presenteeism: as defined by total number of days with symptoms of influenza present at work divided by total number of days due to work in HCW with PCR-proven influenza infection
Time Frame: up to 6 months
Presenteeism: as defined by total number of days with symptoms of influenza present at work divided by total number of days due to work in HCW with PCR-proven influenza infection;
up to 6 months
Compliance with hand hygiene recommendations and cough etiquette (including barrier precautions) in HCW according to repeated observations
Time Frame: up to 6 months
Compliance with hand hygiene recommendations and cough etiquette (including barrier precautions) in HCW according to repeated observations;
up to 6 months
Association of patient and HCW characteristics, including receipt of influenza vaccine, with asymptomatic viral shedding, as compared to symptomatic shedding
Time Frame: up to 6 months
Association of patient and HCW characteristics, including receipt of influenza vaccine, with asymptomatic viral shedding, as compared to symptomatic shedding;
up to 6 months
Association between viral load and asymptomatic or symptomatic transmission based on quantification of viral shedding according to cycle threshold (Ct) values from PCR
Time Frame: up to 6 months
defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e. exceeds background level).
up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stefan Kuster, MD, Division of Infectious Diseases and Hospital Epidemiology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Actual)

June 1, 2017

Study Completion (Actual)

June 1, 2017

Study Registration Dates

First Submitted

June 5, 2015

First Submitted That Met QC Criteria

June 22, 2015

First Posted (Estimate)

June 23, 2015

Study Record Updates

Last Update Posted (Actual)

October 31, 2017

Last Update Submitted That Met QC Criteria

October 30, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Human Influenza

Clinical Trials on Influenza

Subscribe